FDA Brief

Warning letters Drugs

FDA warning letter to

Reliance Life Sciences Private Limited

High riskIssued Aug 18Posted Sep 1Center for Drug Evaluation and Research (CDER)

FDA warned India's Reliance Life Sciences over falsified microbiology records and aseptic failures in sterile drug production, prompting a recall.

What happened

FDA inspected the Navi Mumbai plant from February 19 to 27, 2026 and found that environmental monitoring and other microbial samples were written into logbooks as collected and incubated, but the plates were missing and analysts confirmed the samples were never taken. Investigators also saw operators blocking sterile airflow over critical filling areas, damaged equipment inside aseptic areas, and cleaning with nonsterile wipes. The company agreed on June 19, 2026 to recall all sterile drug products, and FDA placed the firm's imports on Import Alert 66-40 (a list that lets FDA detain a firm's shipments) on July 9, 2026.

What FDA found

  1. Microbial and environmental monitoring samples were recorded as collected and incubated even though the plates could not be found and analysts said the samples were never taken.

    21 CFR 211.194(a)
  2. The lab computer system had no dilution factor, so batches were released on raw plate counts without evidence they met the microbial limit specifications.

    21 CFR 211.194(a)
  3. Electronic leak-test reports were overwritten because files had no unique names, and no such integrity testing was done for one plant, so failed tests could not be traced.

    21 CFR 211.194(a)
  4. Operators blocked first-air (the sterile airflow) over stopper bowls and vials during filling, and potentially compromised vials were not discarded.

    21 CFR 211.113(b)
  5. Equipment inside aseptic areas was deteriorated or damaged, excess sealant sat near HEPA filters, nonsterile wipes were used, and standing water and staining were found nearby.

    21 CFR 211.113(b)
  6. FDA found the quality unit was not enabled to use proper authority and the quality system was not effective.

What FDA wants

FDA asks the company to send a written response within 15 working days covering a full data integrity investigation, retrospective microbial review of U.S. batches, risk assessments, CAPA plans, independent consultant audits and quality unit remediation. The firm must also engage a qualified consultant under 21 CFR 211.34 to audit its whole operation before seeking resolution of its compliance status.

Who should pay attention

  • hospitals, clinics and distributors that hold sterile drugs made at this site
  • US companies that use Reliance Life Sciences as a contract manufacturer
  • quality teams auditing suppliers in India for sterile product

This is a summary. Read the original letter on fda.gov.

Reliance Life Sciences Private Limited's FDA history

Recalls in the last 12 months

Jul 15 Class II Reliance Life Sciences Private Limited
Drug
Pemetrexed for Injection 500mg/Vial, 1 50 mL Single-Dose Vial per carton, For intravenous use only, Rx only, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873 NDC: 70069-0835-01
Lack of Sterility Assurance
Jul 15 Class II Reliance Life Sciences Private Limited
Drug
Bortezomib for Injection 3.5mg/Vial, 10 mL per Single-Dose Vial, For Intravenous or Subcutaneous Use, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873. NDC: 70069-0836-01
Lack of Sterility Assurance
Jul 15 Class II Reliance Life Sciences Private Limited
Drug
Pemetrexed for Injection 100mg/Vial, 1 10 mL Single-Dose Vial per carton, For intravenous use only, Rx only, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873 NDC: 70069-0834-01
Lack of Sterility Assurance
Jul 15 Class II Reliance Life Sciences Private Limited
Drug
Azacitidine for Injection 100mg/Vial, 1 10 mL Single-Dose Vial per carton, For Subcutaneous and Intravenous Use, Rx only, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873 NDC: 70069-0857-01
Lack of Sterility Assurance

Full company page

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk